Product Datasheet

PARG1 Antibody - BSA Free

NBP1-05989

Unit Size: 100 ul

Store at 4C. Do not freeze.

www.novusbio.com technical@novusbio.com

Publications: 13

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP1-05989

Updated 9/9/2025 v.20.1



NBP1-05989

PARG1 Antibody - BSA Free

Product Information

Unit Size	100 ul
Concentration	1.0 mg/ml
Storage	Store at 4C. Do not freeze.
Clonality	Polyclonal
Preservative	0.09% Sodium Azide
Isotype	IgG
Purity	Immunogen affinity purified
Buffer	Tris-Citrate/Phosphate (pH 7.0 - 8.0)

Product Description

Description	Novus Biologicals Rabbit PARG1 Antibody - BSA Free (NBP1-05989) is a polyclonal antibody validated for use in IHC, WB, ICC/IF and IP. Anti-PARG1 Antibody: Cited in 11 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Rabbit
Gene ID	9411
Gene Symbol	ARHGAP29
Species	Human, Mouse
Immunogen	The immunogen recognized by this antibody maps to a region between residue 1211 and 1261 of human PTPL1-associated RhoGAP 1 (NP_004806.3).

Product Application Details

Applications	Western Blot, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunoprecipitation
Recommended Dilutions	Western Blot 1:2000-1:10000, Immunohistochemistry 1:10-1:500, Immunocytochemistry/ Immunofluorescence 1:10-1:500, Immunoprecipitation 2-5 ug/mg lysate
Application Notes	ICC/IF, IHC reactivity reported in scientific literature (PMID: 23008150). Western blot of lysates performed using standard western blot reagents and 4-8% SDS-PAGE.

Images

Western Blot: PARG1 Antibody [NBP1-05989] - Whole cell lysate from HeLa, 293T, and mouse NIH3T3 cells. PARG1 was also immunoprecipitated by rabbit anti-PARG1 antibody NBP1-05988.



(A) Probability of interaction of Rho GTPase activating protein 29 (ARHGAP29) with AKT1, SIRT1, PTPN13, CDC42, MAGEA11, and RHOD. In silico analyses were carried out using the GIANT web server (Genome-wide Integrated Analysis of gene Networks in Tissues, provided by HumanBase, https://hb.flatironinstitute.org/, last accessed on 26 July 2019). A value of 0.1 was chosen as a minimum confidence interval to investigate interactions. The maximum number of genes considered was seven. The color of the connecting lines between interaction partners reflects possible interactions from 0 (no interaction) to 1 (high probability of interaction). The expression of AKT1 and the pAKT1/AKT1 ratio in MCF-7-EMT (B), T-47D-EMT (C), and HCC1806 (D) breast cancer cells after knock-down of ARHGAP29 expression are shown. Breast cancer cells were transiently transfected with ARHGAP29 -specific siRNA or non-targeting control siRNA (control). The expression of AKT1 was determined using Western blot analysis and normalized to GAPDH expression using at least three biological and technical replicates. The pAKT1/AKT1 ratio was analyzed as the quotient of pAKT1 versus AKT1 expression. Representative blots for ARHGAP29, AKT1 and pAKT1 are shown. Mean +/- SEM values are given. Significance was determined with the help of unpaired t-tests; (***) $p < 0.001$; (**) $p < 0.01$; (*) $p < 0.05$. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33291460), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



(A) Probability of interaction of Rho GTPase activating protein 29 (ARHGAP29) with AKT1, SIRT1, PTPN13, CDC42, MAGEA11, and RHOD. In silico analyses were carried out using the GIANT web server (Genome-wide Integrated Analysis of gene Networks in Tissues, provided by HumanBase, https://hb.flatironinstitute.org/, last accessed on 26 July 2019). A value of 0.1 was chosen as a minimum confidence interval to investigate interactions. The maximum number of genes considered was seven. The color of the connecting lines between interaction partners reflects possible interactions from 0 (no interaction) to 1 (high probability of interaction). The expression of AKT1 and the pAKT1/AKT1 ratio in MCF-7-EMT (B), T-47D-EMT (C), and HCC1806 (D) breast cancer cells after knock-down of ARHGAP29 expression are shown. Breast cancer cells were transiently transfected with ARHGAP29 -specific siRNA or non-targeting control siRNA (control). The expression of AKT1 was determined using Western blot analysis and normalized to GAPDH expression using at least three biological and technical replicates. The pAKT1/AKT1 ratio was analyzed as the quotient of pAKT1 versus AKT1 expression. Representative blots for ARHGAP29, AKT1 and pAKT1 are shown. Mean +/- SEM values are given. Significance was determined with the help of unpaired t-tests; (***) $p < 0.001$; (**) $p < 0.01$; (*) $p < 0.05$. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33291460), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



(A) Probability of interaction of Rho GTPase activating protein 29 (ARHGAP29) with AKT1, SIRT1, PTPN13, CDC42, MAGEA11, and RHOD. In silico analyses were carried out using the GIANT web server (Genome-wide Integrated Analysis of gene Networks in Tissues, provided by HumanBase, https://hb.flatironinstitute.org/, last accessed on 26 July 2019). A value of 0.1 was chosen as a minimum confidence interval to investigate interactions. The maximum number of genes considered was seven. The color of the connecting lines between interaction partners reflects possible interactions from 0 (no interaction) to 1 (high probability of interaction). The expression of AKT1 and the pAKT1/AKT1 ratio in MCF-7-EMT (B), T-47D-EMT (C), and HCC1806 (D) breast cancer cells after knock-down of ARHGAP29 expression are shown. Breast cancer cells were transiently transfected with ARHGAP29 -specific siRNA or non-targeting control siRNA (control). The expression of AKT1 was determined using Western blot analysis and normalized to GAPDH expression using at least three biological and technical replicates. The pAKT1/AKT1 ratio was analyzed as the quotient of pAKT1 versus AKT1 expression. Representative blots for ARHGAP29, AKT1 and pAKT1 are shown. Mean +/- SEM values are given. Significance was determined with the help of unpaired t-tests; (***) $p < 0.001$; (**) $p < 0.01$; (*) $p < 0.05$. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33291460), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Tröster B, Kappelmann-Fenzl M, Bosserhoff A et al. Emerging role of ARHGAP29 in melanoma cell phenotype switching. Molecular oncology 2025-09-04 [PMID: 40906537]

Rhea L, Reeb T, Adelizzi E et Al. ARHGAP29 promotes keratinocyte proliferation and migration in vitro and is dispensable for in vivo wound healing Dev Dyn 2024-11-19 [PMID: 39560169]

MAIKE KANSY, KATHARINA WERT, KATHARINA KOLB, JULIA GALLWAS, CARSTEN GRÜNDKER ARHGAP29 Is Involved in Increased Invasiveness of Tamoxifen-resistant Breast Cancer Cells and its Expression Levels Correlate With Clinical Tumor Parameters of Breast Cancer Patients Cancer Genomics & Proteomics 2024-07-03 [PMID: 38944420]

Li MJ, Shi JY, Zhang BH et al. Targeted re-sequencing on 1p22 among non-syndromic orofacial clefts from Han Chinese population Frontiers in genetics 2022-08-17 [PMID: 36061182] (IHC-P, WB, Human)

Reeb T, Rhea L, Adelizzi E et al. ARHGAP29 is required for keratinocyte proliferation and migration bioRxiv : the preprint server for biology 2023-02-01 [PMID: 36778214] (WB, Human)

Kolb K, Hellinger J, Kansy M et al. Influence of ARHGAP29 on the Invasion of Mesenchymal-Transformed Breast Cancer Cells Cells 2020-12-05 [PMID: 33291460] (WB, Human)

Leinhos L Myofibroblast differentiation in hypoxia: a novel role for ArhGAP29 Thesis (WB)

Paul BJ, Palmer K, Sharp JC et al. ARHGAP29 Mutation Is Associated with Abnormal Oral Epithelial Adhesions J. Dent. Res. 2017-08-01 [PMID: 28817352] (WB, Mouse)

Xu Q, Duan H, Gan L et al. MicroRNA-1291 promotes endometrial fibrosis by regulating the ArhGAP29-RhoA/ROCK1 signaling pathway in a murine model Mol Med Rep 2017-08-10 [PMID: 28849001] (IF/IHC, Mouse)

Post A, Pannekoek WJ, Ponsioen B et al. Rap1 spatially controls ArhGAP29 to inhibit Rho signaling during endothelial barrier regulation. Mol. Cell. Biol. 2015-05-11 [PMID: 25963656] (ICC/IF, Human)

Biggs LC, Naridze RL, Demali KA et al. Interferon regulatory factor 6 regulates keratinocyte migration. J. Cell. Sci. 2014-04-28 [PMID: 24777480] (WB, ICC/IF, Mouse)

Post A, Pannekoek WJ, Ross SH et al. Rasip1 mediates Rap1 regulation of Rho in endothelial barrier function through ArhGAP29. Proc Natl Acad Sci U S A 2013-07-09 [PMID: 23798437] (WB, Human)

More publications at http://www.novusbio.com/NBP1-05989

Novus Biologicals USA
10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada
21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd
19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information
www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP1-05989

NBL1-07670	PARG1 Overexpression Lysate
NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP1-05989

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications